295 related articles for article (PubMed ID: 34800920)
21. Comparative evaluation of Sensititre YeastOne and VITEK 2 against the Clinical and Laboratory Standards Institute M27-E4 reference broth microdilution method for the antifungal susceptibility testing of Cryptococcus neoformans and Cryptococcus gattii.
Zhang M; Zhou Z; Wang D; Zhou A; Song G; Chen X; Guo J; Wu W
Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35099022
[TBL] [Abstract][Full Text] [Related]
22. Molecular epidemiology and antifungal susceptibility profiles of clinical
Bandalizadeh Z; Shokohi T; Badali H; Abastabar M; Babamahmoudi F; Davoodi L; Mardani M; Javanian M; Cheraghmakani H; Sepidgar AA; Badiee P; Khodavaisy S; Afshari SAK; Ahmadikia K; Seyedmousavi S
J Med Microbiol; 2020 Jan; 69(1):72-81. PubMed ID: 31750814
[No Abstract] [Full Text] [Related]
23. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
Nascimento E; Vitali LH; Kress MRVZ; Martinez R
Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.
Nooney L; Matthews RC; Burnie JP
Diagn Microbiol Infect Dis; 2005 Jan; 51(1):19-29. PubMed ID: 15629225
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
Mahabeer Y; Chang CC; Naidu D; Dorasamy A; Lewin S; Ndung'u T; Moosa MY; French M; Mlisana K; Coovadia Y
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):294-8. PubMed ID: 25277745
[TBL] [Abstract][Full Text] [Related]
26. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
27. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
28. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Pfaller MA; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
[TBL] [Abstract][Full Text] [Related]
29. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):87-93. PubMed ID: 11035239
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
31. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
[TBL] [Abstract][Full Text] [Related]
32. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
33. Ventriculoperitoneal shunt infection by Cryptococcus neoformans sensu stricto: Case report and literature review.
Kumar A; Udayakumaran S; Sachu A; Shashindran N; Baby P; Thaha A; Kurien A; Chowdhary A
Rev Iberoam Micol; 2022; 39(1):16-20. PubMed ID: 35248468
[TBL] [Abstract][Full Text] [Related]
34. Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS.
Rodero L; Córdoba S; Cahn P; Soria M; Lucarini M; Davel G; Kaufman S; Canteros C; Guelfand L
Med Mycol; 2000 Jun; 38(3):201-7. PubMed ID: 10892987
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
36. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
Brandt ME; Pfaller MA; Hajjeh RA; Hamill RJ; Pappas PG; Reingold AL; Rimland D; Warnock DW;
Antimicrob Agents Chemother; 2001 Nov; 45(11):3065-9. PubMed ID: 11600357
[TBL] [Abstract][Full Text] [Related]
37. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.
Pfaller MA; Zhang J; Messer SA; Brandt ME; Hajjeh RA; Jessup CJ; Tumberland M; Mbidde EK; Ghannoum MA
Antimicrob Agents Chemother; 1999 Jan; 43(1):169-71. PubMed ID: 9869586
[TBL] [Abstract][Full Text] [Related]
38. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Doern GV; Diekema DJ
J Clin Microbiol; 2005 May; 43(5):2163-7. PubMed ID: 15872236
[TBL] [Abstract][Full Text] [Related]
39. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
[TBL] [Abstract][Full Text] [Related]
40. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
Dannaoui E; Abdul M; Arpin M; Michel-Nguyen A; Piens MA; Favel A; Lortholary O; Dromer F;
Antimicrob Agents Chemother; 2006 Jul; 50(7):2464-70. PubMed ID: 16801427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
